- FTC Expands Patent Listing Challenges🔍
- FTC Challenges More Than 100 Patents as Improperly Listed in the ...🔍
- The Current Status of FTC's Orange Book Listings Challenge🔍
- The FTC Challenges Companies' Allegedly Improper Orange Book ...🔍
- FTC Challenges More Patent Listings in the FDA's Orange Book🔍
- The FTC Strikes Again – Challenging the Listing of 300+ Patents in ...🔍
- FTC Ramps Up Efforts to Crackdown on Inaccurate Patent Listings ...🔍
- The FTC's Challenge to the Listing of Device Patents in the Orange ...🔍
FTC Challenges More Patent Listings in the FDA's Orange Book
FTC Expands Patent Listing Challenges, Targeting More Than 300 ...
The Commission sent warning letters to 10 companies and notified the FDA that it disputes the accuracy or relevance of more than 300 Orange Book ...
FTC Challenges More Than 100 Patents as Improperly Listed in the ...
The Commission said improper listings in the Orange Book may harm competition from cheaper generic alternatives and keep brand prices ...
The Current Status of FTC's Orange Book Listings Challenge
After each announcement, the FTC sent patent listing dispute letters to the FDA pursuing removal or correction of the subject Orange Book ...
The FTC Challenges Companies' Allegedly Improper Orange Book ...
The FTC is stepping up its initiative to challenge what it views as improper patent listings in FDA's Orange Book, applying pressure on branded ...
FTC Challenges More Patent Listings in the FDA's Orange Book
The agency believes that improper listing of patents in the Orange Book may be harming competition by (1) blocking FDA approval of a competing generic or ...
The FTC Strikes Again – Challenging the Listing of 300+ Patents in ...
Locke Lord QuickStudy: The FTC Strikes Again – Challenging the Listing of 300+ Patents in FDA's Orange Book ... In the warning letters, the FTC ...
FTC Ramps Up Efforts to Crackdown on Inaccurate Patent Listings ...
FTC Ramps Up Efforts to Crackdown on Inaccurate Patent Listings in the FDA's Orange Book ... The move targets over 300 listings for 20 branded ...
The FTC's Challenge to the Listing of Device Patents in the Orange ...
For each of the thirty-seven drug products, FTC commenced so-called Patent Listing Dispute proceedings, under the auspices of FDA, as opposed to ...
Increased Scrutiny by Federal Trade Commission of Orange Book ...
listing dispute communications with the FDA under 21 C.F.R. 314.53(f)(1), which enables the. FTC to challenge patent listings in the Orange.
The FTC's Challenge to the Listing of Device Patents in the Orange ...
On July 12, 2024, the FDA updated the “Patent Listing Disputes” page on its website. ... While we are not privy to the actual submissions made by ...
FTC continues to scrutinize Orange Book patent listings - DLA Piper
The Federal Trade Commission (FTC) sent its second set of warning letters to 10 companies disputing the accuracy or relevance of more than ...
The FTC's Criticism of “Junk” Orange Book Filings - Ropes & Gray LLP
Federal Trade Commission, FTC Challenges More Than 100 Patents as Improperly Listed in the FDA's Orange Book (November 7, 2023), https://www.ftc ...
Following Recent Policy Statement, FTC 'Disputes' 100+ Patent ...
Following Recent Policy Statement, FTC 'Disputes' 100+ Patent Listings in FDA Orange Book · FTC's 'challenges' are not antitrust enforcement ...
US FTC Continues Aggressive Scrutiny of Pharmaceutical Patents ...
FTC Continues to Ramp Up Scrutiny of Orange Book Patent Listings. These patent listing challenges are just the latest step by the FTC, which has ...
Primer: FTC Scrutinizes Orange Book Listings - AAF
The FTC sent notice letters – the first tranche in November 2023 and the second in April 2024 – to drug manufacturers challenging more than 400 ...
FTC challenges around 100 FDA Orange Book patent listings
In an unprecedented move, FTC has notified 10 companies that FTC is disputing the listings for more than 100 patents in the Orange Book ...
FTC Challenges Over 100 Drug Product Patents Listed in FDA ...
The FTC's warning letters to manufacturers maintain the position that improperly listing patents in the Orange Book may violate antitrust laws.
FTC Weighs In on Orange Book Listing of Drug-Device Patents
To date, however, FDA has not provided any more guidance about whether or to what extent such patents are properly listable in the Orange Book.
FTC Challenges 100+ Patents, Bringing Attention to Orange Book ...
On November 7, 2023, the Federal Trade Commission (FTC) officially challenged more than 100 patents that brand name drug manufacturers have ...
Patent Listing in FDA's Orange Book - CRS Reports
In November 2023, FTC announced that it had used FDA's administrative process to challenge more than 100 patents as improperly listed in the ...